The landscape of T-cell engagers for the treatment of follicular lymphoma Review
| Authors: | Rivas-Delgado, A.; Landego, I.; Falchi, L. |
| Review Title: | The landscape of T-cell engagers for the treatment of follicular lymphoma |
| Abstract: | Follicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, relies on interactions with immune elements in the tumor microenvironment, including T-follicular helper cells and follicular dendritic cells, for its survival and progression. Despite its initial responsiveness to chemoimmunotherapy, FL is generally considered incurable. Strategies to improve immune-mediated control of FL could significantly benefit this population, particularly as it includes many elderly and comorbid patients. Immune cell engagers, especially bispecific antibodies (BsAbs), are crucial in targeting FL by bridging tumor and effector cells, thereby triggering T-cell activation and cytotoxic killing. CD3 × CD20 BsAbs have shown the most promise in clinical development for B-NHL patients, with structural variations affecting their target affinity and potency. This review summarizes the current clinical trials of BsAbs for relapsed/refractory FL, highlighting the approval of some agents, their role in first-line treatment or combination therapies, their toxicity profiles, and the future of this therapeutic approach compared to other immune cell therapies. © 2024 The Author(s). Published with license by Taylor & Francis Group, LLC. |
| Keywords: | overall survival; lenalidomide; neutropenia; cancer growth; monotherapy; clinical trials as topic; note; rituximab; t lymphocyte; t-lymphocytes; cancer immunotherapy; progression free survival; dendritic cell; dexamethasone; drug effect; cd20 antigen; immunology; immunotherapy; drug therapy; cell activation; follicular lymphoma; lymphoma, follicular; disease exacerbation; therapy; immunocompetent cell; helper cell; cd33 antigen; non-hodgkin lymphoma; immunization; tumor microenvironment; clinical trial (topic); procedures; antibodies, bispecific; bispecific antibody; humans; human; bispecific antibodies; immunological antineoplastic agent; antineoplastic agents, immunological; mosunetuzumab; odronextamab; epcoritamab; glofitamab |
| Journal Title: | OncoImmunology |
| Volume: | 13 |
| Issue: | 1 |
| ISSN: | 2162-4011 |
| Publisher: | Landes Bioscience |
| Date Published: | 2024-01-01 |
| Start Page: | 2412869 |
| Language: | English |
| DOI: | 10.1080/2162402x.2024.2412869 |
| PUBMED: | 39398477 |
| PROVIDER: | scopus |
| PMCID: | PMC11468044 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Source: Scopus |
